Jennifer A. Whitaker

MedicineSocial Sciences

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 18 papers. Top paper: “Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant”.

Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant

Cell Reports Medicine(2022)10.1016/j.xcrm.2022.100679

N/A

5.1DataRank · unranked

167 citations

Robert L. Atmar, Clara Domínguez Islas, Christine M. Posavad, Daniel Szydlo, Rahul Paul Chourdhury +64 more

SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses

medRxiv(2022)10.1101/2022.07.12.22277336

N/A

1.6DataRank · unranked

30 citations

Nadine Rouphael, David Diemert, Ann R. Falsey, Cecilia Losada, Lindsey R. Baden +63 more

Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial

Nature Medicine(2023)10.1038/s41591-023-02503-4

N/A

1.3DataRank · unranked

56 citations

Nadine Rouphael, David Diemert, Ann R. Falsey, Cecilia Losada, Lindsey R. Baden +94 more

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants

npj Vaccines(2023)10.1038/s41541-023-00693-z

N/A

1.1DataRank · unranked

33 citations

Robert L. Atmar, Clara Domínguez Islas, Christine M. Posavad, Meagan E. Deming, Angela R Branche +69 more

Relative Effectiveness and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Versus Egg-Based Inactivated Influenza Vaccine Among Adults Aged 18–64 Years: Results and Experience From a Randomized, Double-Blind Trial

Open Forum Infectious Diseases(2024)10.1093/ofid/ofae559

N/A

0.585DataRank · unranked

11 citations

Jennifer A. Whitaker, Sarang K. Yoon, Karen Lutrick, S. K. Bhargava, C Perry Brown +27 more

Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial

Annals of Internal Medicine(2022)10.7326/m22-2116

N/A

0.434DataRank · unranked

6 citations

Tyler Bonnett, Kevin Rubenstein, David A Lindholm, Rekha R. Rapaka, Sarah B. Doernberg +39 more

A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults

Clinical Infectious Diseases(2024)10.1093/cid/ciae173

N/A

0.384DataRank · unranked

11 citations

Robert L. Atmar, Emmanuel B. Walter, Sharon E. Frey, Jeffery L. Meier, Amy C Sherman +23 more

Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) Trial

Research Square(2023)10.21203/rs.3.rs-2653179/v1

N/A

0.372DataRank · unranked

5 citations

Nadine Rouphael, David Diemert, Ann R. Falsey, Cecilia Losada, Lindsey R. Baden +63 more

Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial

The Journal of Infectious Diseases(2023)10.1093/infdis/jiad276

N/A

0.312DataRank · unranked

7 citations

İnci Yıldırım, Sharon E. Frey, Patricia Winokur, Lisa A. Jackson, David I. Bernstein +26 more

Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial

Clinical Infectious Diseases(2024)10.1093/cid/ciae465

N/A

0.251DataRank · unranked

3 citations

Lauren Dang, Bo Zhang, Jonathan Fintzi, Shiyu Chen, Jing Wang +84 more

A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18–45 years of age

Vaccine(2025)10.1016/j.vaccine.2025.126991

N/A

0.226DataRank · unranked

3 citations

Emmanuel B. Walter, Michael J. Smith, James Campbell, Hana M. El Sahly, Jennifer A. Whitaker +20 more

Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial

medRxiv(2023)10.1101/2023.01.31.23285306

N/A

0.104DataRank · unranked

1 citations

Nadine Rouphael, Cecilia Losada, Lindsey R. Baden, Evan J. Anderson, Anne F. Luetkemeyer +31 more

COVID-19 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized Controlled Trials

Clinical Infectious Diseases(2024)10.1093/cid/ciae192

N/A

0DataRank · unranked

6 citations

Jessica Tuan, Valeria D Cantos, Oladunni Adeyiga, Scott Mahoney, Ana M. Ortega‐Villa +25 more

Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial

medRxiv(2023)10.1101/2023.06.06.23290973

N/A

0DataRank · unranked

0 citations

Angela R Branche, David Diemert, Ann R. Falsey, Cecilia Losada, Lindsey R. Baden +31 more

Long-term safety and efficacy of COVE study open-label and booster phases

Research Square(2024)10.21203/rs.3.rs-3900939/v1

N/A

0DataRank · unranked

0 citations

Hana M. El Sahly, Brandon Essink, Dean Follmann, Gregory Hachigian, Cynthia Strout +19 more

Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost

Nature Communications(2025)10.1038/s41467-025-55931-w

N/A

0DataRank · unranked

9 citations

Youyi Fong, Lauren Dang, Jonathan Fintzi, Shiyu Chen, Jing Wang +43 more

The Coronavirus Disease 2019 Pandemic Unmasked the Challenges Faced by Early-Stage Faculty in Infectious Diseases: A Call to Action

Clinical Infectious Diseases(2022)10.1093/cid/ciac779

N/A

0DataRank · unranked

5 citations

Martín Bäcker, Karen Carvajal, Lara Danziger‐Isakov, Sharon E. Frey, Leigh M. Howard +12 more

Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive Coronavirus Disease 2019 Treatment Trial (ACTT) as a Test Case

Open Forum Infectious Diseases(2023)10.1093/ofid/ofad290

N/A

0DataRank · unranked

2 citations

Noreen A. Hynes, Corri B. Levine, Katherine Yang, Zanthia Wiley, Nikolaus Jilg +37 more